SCHEMBL5545406

SCHEMBL5545406

CCCCCCCCC1CCCC1CCCCCCC(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.69
GPR84 Q9NQS5 7/20 0.61
PPARG P37231 7/20 0.61
PPARD Q03181 7/20 0.61
PPARA Q07869 7/20 0.61
HDAC11 Q96DB2 5/20 0.61
TSHR P16473 4/20 0.61
PTPN1 P18031 3/20 0.61
ALDH1A1 P00352 2/20 0.61
TLR2 O60603 2/20 0.61
TDP1 Q9NUW8 2/20 0.61
FABP4 P15090 2/20 0.61
KMT2A Q03164 2/20 0.61
ALOX15 P16050 2/20 0.61
HSD17B10 Q99714 2/20 0.61
SLC22A6 Q4U2R8 1/20 0.61
SLC22A8 Q8TCC7 1/20 0.61
MEN1 O00255 1/20 0.61
ESR1 P03372 1/20 0.61
PDE4A P27815 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10580840 1.00 ALOX5 (0.69) ALOX5GPR84PPARGPPARDPPARA
SCHEMBL9513062 1.00 ALOX5 (0.69) ALOX5GPR84PPARGPPARDPPARA
SCHEMBL126631 1.00 ALOX5 (0.69) ALOX5GPR84PPARGPPARDPPARA
SCHEMBL862219 1.00 ALOX5 (0.69) ALOX5GPR84PPARGPPARDPPARA
SCHEMBL21941814 1.00 ALOX5 (0.69) ALOX5GPR84PPARGPPARDPPARA
Hydrochloric Acid SCHEMBL11739322 0.98 ALOX5 (0.67) ALOX5GPR84PPARGPPARDPPARA
Hydrogen Sulfide SCHEMBL27802019 0.98 ALOX5 (0.67) ALOX5GPR84PPARGPPARDPPARA
Charcoal, Activated SCHEMBL5436853 0.98 ALOX5 (0.67) ALOX5GPR84PPARGPPARDPPARA
SCHEMBL11239681 0.96 ALOX5 (0.64) ALOX5GPR84PPARGPPARDPPARA
SCHEMBL9623339 0.96 ALOX5 (0.69) ALOX5GPR84PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9849122-B2 Combination therapy AERIE PHARMACEUTICALS, INC. (US) 2017-12-26 US disclosed
US-9254326-B2 Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound R-TECH UENO, LTD. (JP) 2016-02-09 US disclosed
US-20150126609-A1 PHARMACEUTICAL COMPOSITION COMPRISING 11-DEOXY -PROSTAGLANDIN COMPOUND AND METHOD FOR STABILIZING THE COMPOUND SUCAMPO AG (CH) 2015-05-07 US disclosed
US-8969324-B2 Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound R-TECH UENO, LTD. (JP) 2015-03-03 US disclosed
US-8962688-B2 Method for the treatment of gastrointestinal disorders SUCAMPO AG (CH) 2015-02-24 US disclosed
US-20140315994-A1 METHOD FOR TREATING GASTROINTESTINAL DISORDER SUCAMPO AG (CH) 2014-10-23 US disclosed
US-8569058-B2 Nerve regeneration promoters ONO PHARMACEUTICAL CO., LTD. (JP) 2013-10-29 US disclosed
US-8569058-B2 Nerve regeneration promoters ONO PHARMACEUTICAL CO., LTD. (JP) 2013-10-29 US disclosed
US-8513441-B2 Prostaglandin synthesis and intermediates for use therein ALPHORA RESEARCH INC. (CA) 2013-08-20 US disclosed
US-20130072695-A1 PROSTAGLANDIN SYNTHESIS AND INTERMEDIATES FOR USE THEREIN ALPHORA RESEARCH INC. (CA) 2013-03-21 US disclosed
US-3936487-A RACEMIC MIXTURES, ANTIULCER, ANTICOAGULANT, LABOR INDUCING THE UPJOHN COMPANY (US) 1976-02-03 US disclosed
US-3933889-A 4,5-Cis-didehydro-PGF1.sub.α analogs THE UPJOHN COMPANY (US) 1976-01-20 US disclosed
US-3933897-A ANTIULCER, ASTHMA, RENAL DYSFUNCTION THE UPJOHN COMPANY (US) 1976-01-20 US disclosed
US-3933895-A PROSTAGLANDINS, ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING THE UPJOHN COMPANY (US) 1976-01-20 US disclosed
US-3933900-A ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING THE UPJOHN COMPANY (US) 1976-01-20 US disclosed
US-3933898-A ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING THE UPJOHN COMPANY (US) 1976-01-20 US disclosed
US-3933896-A ANTICOAGULANTS, ASTHMA, LABOR INDUCERS, CERVICAL DILATION THE UPJOHN COMPANY (US) 1976-01-20 US disclosed
US-3933899-A ANTIULCER, ANTICOAGULANTS, NASAL PATENCY, LABOR INDUCERS, WOUND HEALING THE UPJOHN COMPANY (US) 1976-01-20 US disclosed
US-3931279-A 5-Oxa prostaglandin F2.sub.α analogs THE UPJOHN COMPANY (US) 1976-01-06 US disclosed
US-3931289-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072695-A1 PROSTAGLANDIN SYNTHESIS AND INTERMEDIATES FOR USE THEREIN ALOX5, PTGES, PTGIS ALOX5 1/4885GPR84 1152/4885PPARG 328/4885
US-20150126609-A1 PHARMACEUTICAL COMPOSITION COMPRISING 11-DEOXY -PROSTAGLANDIN COMPOUND AND METHOD FOR STABILIZING THE COMPOUND PTGER1, PTGES, PTGIS ALOX5 12/4885GPR84 2271/4885PPARG 54/4885
US-20140315994-A1 METHOD FOR TREATING GASTROINTESTINAL DISORDER SLC10A2, FABP6, FABP2 ALOX5 16/4885GPR84 1408/4885PPARG 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.